I don't understand what your criticism is here exactly. Of course Eli Lilly will release a press release if the results of a clinical trial are good but that doesn't make the underlying research (published in the Lancet [1]) suspect in any way. Clinical trials are overseen by the FDA and frequently conducted by third party research scientists without a financial stake in the long term success of the intervention being studied. In this case, it appears that the study authors were researchers at Velocity Clinical Research and they found significant body weight loss with side effects comparable with other GLP-1 agonists. Skepticism might be warranted, particularly until phase 3 trials are conducted, but mindless cynicism hardly seems warranted.
We actually have a lot of data on Ozempic and GLP-1s generally, going back to the first GLP-1 FDA approval in 2005:
• Exenatide - FDA approved in 2005
• Liraglutide / Saxenda - FDA approved in 2010
• Dulaglutide / Trulicity - FDA approved in 2014
• Semaglutide / Ozempic/Wegovy - FDA approved in 2017
• Tirzepatide / Mounjaro - FDA approved in 2022
Ozempic / Semaglutide was FDA approved in 2017, but clinical trials started in 2008. That was 16 years ago. Obviously it's always possible there are even longer term side effects we're unaware of, but generally if this class of drug caused large scale problems for kidneys, liver, etc, we'd likely know by now.
Typically, I run through lists like to-dos for companies/projects, the day's agenda, topics/ideas, recollection of the previous day, reflection on mental and emotional state.
Some days are more structured than others, and I don't try to conform too tightly to any particular structure. The goal is to get my brain outputting something, and later in my morning I'll transform or rewrite whatever I spit out. During very busy or demanding periods this also ends up functioning as my primary daily journal entry.
Bc none of the features are actually live yet. We keep hearing about what will be released and demos - but HN is mainly do-ers. Their launches would have 100x the impact if people could see and play with it in real time right after the announcement.
Last I heard they have $1B in cash on hand and are doing roughly $3B/year in revenue. Musk has reportedly gotten their annual expenses down to $3B with another $1.5B in annual debt servicing costs.
That's pretty substantial. Obviously no one knows what Phase 3 will show, but cynicism seems unwarranted at this point.
https://investor.lilly.com/news-releases/news-release-detail...